USPTO serial 97442064
YOCHANRA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 28, 2024
- Examiner
- MAYES, LAURIE ANN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with YOCHANRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
TransThera Sciences (Nanjing), Inc.
Nanjing, Jiangsu, CN
Other trademarks owned by TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc.
Nanjing, Jiangsu, CN
Other trademarks owned by TransThera Sciences (Nanjing), Inc.
TransThera Sciences (Nanjing), Inc.
Nanjing, Jiangsu, CN
Other trademarks owned by TransThera Sciences (Nanjing), Inc.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael T. Smith
Michael T. Smith Birch Stewart Kolasch & Birch, LLP8110 Gatehouse Road, Suite 100 EastFalls Church, VA 22042UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; drugs for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemico-pharmaceutical preparations for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biological preparations for medical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; bulk medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; biochemical medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines in the nature of tablets for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders; medicines for human purposes for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders in the nature of capsule; injectable medicines for treatment of cancer, cardiovascular diseases and disorders, metabolic diseases and disorders, anemia and associated anemia diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, nervous system diseases and disorders, infection and inflammation, skeletal or chondrocyte disorders, immune and autoimmune diseases, hematological disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TransThera Sciences (Nanjing), Inc.
- Other trademarks owned by TransThera Sciences (Nanjing), Inc.
- Other trademarks owned by TransThera Sciences (Nanjing), Inc.
- Other trademarks in Class 005
- Similar marks named YOCHANRA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 28, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 12, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 12, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 21, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 21, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 8, 2024 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Feb 7, 2024 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Feb 7, 2024 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Feb 6, 2024 | APET | ASSIGNED TO PETITION STAFF | — |
| Jan 10, 2024 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Dec 12, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 9, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 9, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 9, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 9, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 9, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 17, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 17, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 12, 2023 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| Sep 12, 2023 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Sep 12, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 28, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 28, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 28, 2023 | ALIE | ASSIGNED TO LIE | — |
| Apr 14, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 3, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 3, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 25, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 14, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 13, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 7, 2022 | NWAP | NEW APPLICATION ENTERED | — |